全文获取类型
收费全文 | 164737篇 |
免费 | 16834篇 |
国内免费 | 11431篇 |
专业分类
耳鼻咽喉 | 1198篇 |
儿科学 | 2232篇 |
妇产科学 | 1514篇 |
基础医学 | 14980篇 |
口腔科学 | 3019篇 |
临床医学 | 22494篇 |
内科学 | 19672篇 |
皮肤病学 | 1906篇 |
神经病学 | 6037篇 |
特种医学 | 5985篇 |
外国民族医学 | 55篇 |
外科学 | 14920篇 |
综合类 | 36659篇 |
现状与发展 | 46篇 |
一般理论 | 8篇 |
预防医学 | 15368篇 |
眼科学 | 4125篇 |
药学 | 18782篇 |
265篇 | |
中国医学 | 13018篇 |
肿瘤学 | 10719篇 |
出版年
2024年 | 644篇 |
2023年 | 2457篇 |
2022年 | 6245篇 |
2021年 | 7865篇 |
2020年 | 6428篇 |
2019年 | 4774篇 |
2018年 | 4877篇 |
2017年 | 5461篇 |
2016年 | 4599篇 |
2015年 | 7734篇 |
2014年 | 9536篇 |
2013年 | 9887篇 |
2012年 | 14708篇 |
2011年 | 15691篇 |
2010年 | 12185篇 |
2009年 | 10194篇 |
2008年 | 11168篇 |
2007年 | 10641篇 |
2006年 | 9464篇 |
2005年 | 8348篇 |
2004年 | 5691篇 |
2003年 | 5182篇 |
2002年 | 4154篇 |
2001年 | 3247篇 |
2000年 | 2731篇 |
1999年 | 2031篇 |
1998年 | 1120篇 |
1997年 | 1183篇 |
1996年 | 898篇 |
1995年 | 758篇 |
1994年 | 697篇 |
1993年 | 392篇 |
1992年 | 353篇 |
1991年 | 342篇 |
1990年 | 294篇 |
1989年 | 229篇 |
1988年 | 221篇 |
1987年 | 190篇 |
1986年 | 126篇 |
1985年 | 95篇 |
1984年 | 46篇 |
1983年 | 43篇 |
1982年 | 18篇 |
1981年 | 13篇 |
1980年 | 8篇 |
1979年 | 15篇 |
1978年 | 2篇 |
1975年 | 4篇 |
1974年 | 3篇 |
1973年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
Ju Zou Daichao Wu Tao Li Xianwen Wang Yan Liu Sijie Tan 《Pathology, research and practice》2019,215(2):229-234
Programmed death ligand 1(PD-L1) mediated immune escape play important roles in the development of cancer. The gene polymorphism of PD-L1, in particular rs4143815 C?>?G, has been associated with the cancer risks, but with conflicting results. Therefore, this meta-analysis was aimed to assess the association between rs4143815 C?>?G and cancer susceptibility. A systematic literature search was performed to select the studies and the pooled odds ratio (OR) with 95% confidence interval (CI) was used to evaluate the strength of association. Eleven eligible studies containing 3711 cases and 3704 controls were enrolled in the meta-analysis. The results suggested that there is a strong association between rs4143815 C?>?G and the cancer risks (G vs. C: OR?=?1.386, 95% CI: 1.132–1.696, p?=?0.002; GG vs. CG?+?CC: OR?=?1.843 95% CI: 1.300–2.613, p?=?0.002; GG?+?CG vs. CC: OR?=?1.280, 95% CI: 1.040–1.576, p?=?0.020). Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C?>?G might increase the susceptibility to gastric cancer (G vs. C: OR?=?1.842, 95% CI: 1.403–2.418, p?<?0.001) and bladder cancer (G vs. C: OR?=?2.015, 95% CI: 1.556–2.608, p?<?0.001), and genotype GG carriers of PD-L1 rs4143815 C?>?G might have higher risks of HCC (GG vs. CG?+?CC: OR?=?2.226 95% CI: 1.562–3.172, p?<?0.001). PD-L1 rs4143815 C?>?G might confer an increased cancer risk, indicating this SNP may contribute to the pathogenesis of cancer and might be used as a potential biomarker to predict the susceptibility to cancer. 相似文献
44.
45.
46.
Xiaojie Wu Leyan Zhang Jiadi Zhou Luying Liu Qiang Fu Aili Fu Xiaoying Feng Rui Xin Hongrui Liu Yong Gao Jiangnan Xue 《Current problems in cancer》2019,43(1):18-26
Aim
Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is an immune inhibitory receptor which is expressed within most types of hematopoietic cells and negatively regulates immune responses. Recently, we found LAIR-1 expression to be present within tumors of nonhematopoietic lineages. However, the roles of LAIR-1 in hepatocellular carcinoma (HCC) have yet to be examined. The purpose of this study was to investigate the expression of LAIR-1 in HCC tissue and assess its clinical significance at this site.Materials and methods
Expression levels of LAIR-1 within HCC samples collected from 90 patients and compared with that of slides of normal liver tissue collected from 9 non-HCC patients were measured by immunohistochemistry using tissue microarrays. A semiquantitative score was assigned, as was based on staining intensity and percent of positive cells and a Spearman Rank correlation test was used to assess any potential significant correlations between LAIR-1 expression and clinicopathological factors. Overall survival analysis was performed using the Kaplan-Meier and Log Rank statistical test.Results
LAIR-1 expression was detected in cancer tissue and adjacent tumor tissue, but not in normal liver tissue. The percent of LAIR-1-positive expression in cancer tissue of HCC samples was 97.78% (88/90) while that in adjacent tumor tissue was 96.67% (87/90). Significantly greater expression levels of LAIR-1 were obtained from cancer tissue (Mean?±?SD?=?5.722?±?2.145) than that in adjacent tumor tissue (4.141?±?1.486). In addition, LAIR-1 expression was found to be significantly correlated with pathological grade of HCC, T stage, and age. Expression levels of LAIR-1 were related with worse overall survival rates of HCC patients, especially in HCC patients with hepatic cirrhosis.Conclusion
Results of this study show that LAIR-1 is expressed in HCC tissues and that high levels of LAIR-1 expression are associated with the poor cancer differentiation. In addition, overexpression of LAIR-1 was significantly associated with worse overall survival in the patients with HCC. These data suggest that LAIR-1 may be an independent predictor for clinical outcomes in patients with HCC. 相似文献47.
目的:总结主动脉窦瘤破裂的手术适应症、手术方法和预后。方法:回顾性分析2011年1月至2017年12月因主动脉窦瘤破裂于我院行外科手术治疗的130名患者资料。其中男性58例(44.62%),女性72例(55.38%),年龄32~75(52.72±13.87)岁。合并室间隔缺损55例(42.31%),合并主动脉瓣关闭不全39例(30%),合并房间隔缺损12例(9.23%),合并三尖瓣关闭不全8例(6.15%),合并二尖瓣关闭不全6例(4.62%),合并主动脉夹层1例(0.77%),合并其他心脏疾病9例(6.92%);破裂开口起源于右冠窦119例,起源于无冠窦11例。所有患者均在中低温体外循环下行手术治疗。结果:所有患者中,2例患者围术期死亡,余128例患者随访5个月至5年,术后心功能恢复至I-II级。结论:一旦发现主动脉窦瘤破裂,应积极予以治疗。 相似文献
48.
基于调控肠道菌群探讨中药防治脑卒中 总被引:3,自引:3,他引:0
肠道菌群是一个独特的生态系统,被称为人体"被遗忘的器官",被誉为人类的"第二基因组"。肠道菌群失调与许多中枢神经系统疾病相关,例如帕金森病、阿尔茨海默症、精神分裂症及多发性硬化等。脑卒中具有高的发病率、复发率、死亡率和致残率的特点。肠道菌群在脑卒中的发生、发展中起着关键的作用,可通过影响机体的吸收、代谢、血压、血糖、血脂及动脉粥样斑块等因素,进一步影响脑卒中的发病。中医认为脾胃气血流注失度、阴阳盛衰失衡,机体生理功能失调,化生"风、火、痰、虚、瘀"等病理产物,可致中风的发生。脾胃主腐熟运化水谷,肠道菌群影响饮食的消化吸收,现代研究的肠道菌群功能与中医之脾胃功能失调相关。因此,调整肠道菌群的稳态,可作为一个潜在的干预靶点预防和治疗缺血性脑卒中。中药干预脑卒中已经取得了很好的疗效,是否与调节肠道菌群有关,值得未来做进一步的研究。同时对中药有效成分(小檗碱、黄芩苷、白藜芦醇等),中药单方(丹参、红景天等)和中药组方(补阳还五汤、脑心通胶囊、补中益气汤等)防治脑缺血的研究进展进行综述,为缺血性脑卒中的预防和开发提供新的途径和思路。 相似文献
49.
50.
Calculus bovis is commonly used for the treatment of stroke in traditional Chinese medicine. Hyodeoxycholic acid(HDCA) is a bioactive compound extracted from calculus bovis. When combined with cholic acid, baicalin and jas-minoidin, HDCA prevents hypoxia-reoxygenation-induced brain injury by suppressing endoplasmic reticulum stress-mediated apoptotic signaling. However, the effects of HDCA in ischemic stroke injury have not yet been studied. Neurovascular unit(NVU) dysfunction occurs in ischemic stroke. Therefore, in this study, we investigated the effects of HDCA on the NVU under ischemic conditions in vitro. We co-cultured primary brain microvascular endothelial cells, neurons and astrocytes using a transwell chamber co-culture system. The NVU was pre-treated with 10.16 or 2.54 μg/mL HDCA for 24 hours before exposure to oxygen-glucose deprivation for 1 hour. The cell counting kit-8 assay was used to detect cell activity. Flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling were used to assess apoptosis. Enzyme-linked immunosorbent assay was used to measure the expression levels of inflammatory cytokines, including interleukin-1β, interleukin-6 and tumor necrosis factor-α, and neurotrophic factors, including brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. Oxidative stress-related factors, such as superoxide dismutase, nitric oxide, malondialdehyde and γ-glutamyltransferase, were measured using kits. Pretreatment with HDCA significantly decreased blood-brain barrier permeability and neuronal apoptosis, significantly increased transendothelial electrical resistance and γ-glutamyltransferase activity, attenuated oxidative stress damage and the release of inflammatory cytokines, and increased brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression. Our findings suggest that HDCA maintains NVU morphological integrity and function by modulating inflammation, oxidation stress, apoptosis, and the expression of neurotrophic factors. Therefore, HDCA may have therapeutic potential in the clinical management of ischemic stroke. This study was approved by the Ethics Committee of Experimental Animals of Beijing University of Chinese Medicine(approval No. BUCM-3-2016040201-2003) in April 2016. 相似文献